

World Journal of *Diabetes*

World J Diabetes 2016 April 25; 7(8): 165-176





Editorial Board

2016-2019

The *World Journal of Diabetes* Editorial Board now consists of 676 members, representing a team of worldwide experts in diabetes mellitus. They are from 56 countries, including Argentina (1), Australia (26), Austria (9), Belgium (5), Brazil (11), Canada (24), Chile (3), China (39), Cuba (1), Czech Republic (2), Denmark (12), Egypt (3), Finland (5), France (11), Germany (26), Greece (16), Hungary (4), Iceland (1), India (24), Iran (6), Iraq (2), Ireland (4), Israel (9), Italy (54), Japan (30), Jordan (1), Kuwait (3), Lebanon (1), Malaysia (1), Malta (1), Mexico (4), Netherlands (7), New Zealand (3), Nigeria (2), Norway (2), Oman (3), Pakistan (2), Poland (8), Portugal (1), Qatar (1), Romania (2), Singapore (4), Slovakia (1), South Africa (1), South Korea (15), Spain (25), Sweden (6), Switzerland (3), Thailand (4), Tunisia (1), Turkey (13), United Arab Emirates (3), United Kingdom (28), United States (199), Venezuela (2), and Yemen (1).

EDITORS-IN-CHIEF

Lu Qi, *Boston*
Jingbo Zhao, *Aarhus*

ASSOCIATE EDITORS

Giovanni Dapri, *Brussels*
Undurti N Das, *Federal Way*
Min Du, *Laramie*
Edward B Jude, *Ashton under Lyne*
Gregory I Liou, *Augusta*
JuanFNavarro-Gonzalez, *Santa Cruz de Tenerife*
Katarzyna Szkudelska, *Poznan*
Richard Welbourn, *Taunton*
Silvano Zanuso, *Chatam Maritime*

GUEST EDITORIAL BOARD MEMBERS

Juei-Tang Cheng, *Tainan*
Chih-Hsung Chu, *Kaohsiung*
Low-Tone Ho, *Taipei*
Cheng-Cheng Hsiao, *Keelung*
Yung-Hsi Kao, *Taoyuan*
Chi-Feng Liu, *Taipei*
Shing-Hwa Liu, *Taipei*
Wayne HH Sheu, *Taichung*
Eing-Mei Tsai, *Kaohsiung*
Chin-Hsiao Tseng, *Taipei*
Wei-Chung V Yang, *Taipei*
Wen-Chin Yang, *Taipei*
Tzung-Hai Yen, *Taipei*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Eduardo Spinedi, *La Plata*



Australia

Sof Andrikopoulos, *Heidelberg*
Hugh R Barrett, *Western*
Bernhard T Baune, *Townsville*
Grant D Brinkworth, *Adelaide*
Melinda T Coughlan, *Melbourne*
Josephine M Forbes, *Melbourne*
Paul A Fournier, *Perth*
Angela Gialamas, *Adelaide*
Mark D Gorrell, *Sydney*
Graeme J Hankey, *Perth*
Anandwardhan A Hardikar, *Melbourne*
Michael Horowitz, *Adelaide*
Karin Jandeleit-Dahm, *Balwyn*
Martha Lappas, *Victoria*
Peter J Little, *Victoria*
Xin Liu, *Brisbane*
Dianna J Magliano, *Caulfield*
Louise JM Maple-Brown, *Casuarina*
Robyn McDermott, *Adelaide*
Beverly S Muhlhauser, *Semaphore*
Christopher J Nolan, *Canberra*
Luciano Pirola, *Melbourne*
Karly C Sourris, *Melbourne*
Greg Tesch, *Victoria*
Jack R Wall, *Penrith*
Owen L Woodman, *Victoria*



Austria

Christian H Anderwald, *Vienna*
Helmuth M Borkenstein, *Graz*

Latife Bozkurt, *Vienna*
Walter H Horl, *Vienna*
Friedrich Mittermayer, *Vienna*
Markus Paulmichl, *Salzburg*
Stefan Pilz, *Graz*
Thomas M Stulnig, *Vienna*
Ludwig Wagner, *Vienna*



Belgium

Christophe De Block, *Edegem*
Ekaterine Tskitishvili, *Liege*
F A Van Assche, *Leuven*
Luc F Van Gaal, *Edegem*



Brazil

Monica L Andersen, *Sao Paulo*
Claudia RL Cardoso, *Rio de Janeiro*
Ricardo V Cohen, *Sao Paulo*
Cassiano J Correr, *Curitiba*
Cintia C Curioni, *Rio de Janeiro*
Freddy G Eliaschewitz, *Sao Paulo*
Rodrigo Jorge, *Ribeirao Preto*
Luciana A Naves, *Brasilia*
Matheus Roriz Cruz, *Porto Alegre*
Júlio C Voltarelli, *Sao Paulo*
Jacqueline N Zanoni, *Maringá*



Canada

Jean-Luc Ardilouze, *Sherbrooke*

Subrata Chakrabarti, *London*
 David ZI Cherney, *Toronto*
 Mervyn Deitel, *Toronto*
 Jean-Pierre Despres, *Québec*
 David J Hill, *Ontario*
 Tian-Ru Jin, *Toronto*
 Arulmozhi D Kandasamy, *Alberta*
 Jennifer L Kuk, *Toronto*
 Ismail Laher, *Vancouver*
 Zhong-Cheng Luo, *Montreal*
 Roger S McIntyre, *Toronto*
 David Meyre, *Hamilton*
 JF Ndisang, *Saskatoon*
 Raj S Padwal, *Alberta*
 Ciriaco A Piccirillo, *Montreal*
 AM James Shapiro, *Edmonton*
 Guang Sun, *St. John's*
 Valerie Taylor, *Ontario*
 Cory Toth, *Calgary*
 André Tremblay, *Montréal*
 VVincent C Woo, *Manitoba*
 James R Wright, *Alberta*
 Xi-Long Zheng, *Calgary*



Chile

Sebastian S Martin, *Valparaiso*
 Armando Rojas Rubio, *Talca*
 Luis Sobrevia, *Santiago*



China

Jie Chen, *Nanjing*
 Bernard Man Yung Cheung, *Hong Kong*
 William CS Cho, *Hong Kong*
 Tian-Pei Hong, *Beijing*
 Qin Huang, *Shanghai*
 Po-Sing Leung, *Hong Kong*
 Chao Liu, *Nanjing*
 Jian-Kang Liu, *Xi'an*
 Lie-Gang Liu, *Wuhan*
 Ronald CW Ma, *Hong Kong*
 Zengchang Pang, *Qingdao*
 Jin-Sheng Qi, *Shijiazhuang*
 Jin-Xiong She, *Shijiazhuang*
 Wing Y So, *Hong Kong*
 Cheuk C Szeto, *Hong Kong*
 Kathryn CB Tan, *Hong Kong*
 Cong-Yi Wang, *Wuhan*
 Yu Wang, *Hong Kong*
 Guang-Da Xiang, *Wuhan*
 Bao-Feng Yang, *Harbin*
 Shu-Yu Yang, *Xiamen*
 Xi-Lin Yang, *Hong Kong*
 Zai-Qing Yang, *Wuhan*
 Shan-Dong Ye, *Hefei*
 Shi-Sheng Zhou, *Dalian*
 Zhi-Guang Zhou, *Changsha*



Cuba

Luis Sarmiento-Pérez, *Havana*



Czech Republic

Michal Krcma, *Plzen*
 Terezie Pelikanova, *Prague*



Denmark

Charlotte Brons, *Gentofte*
 Flemming Dela, *Copenhagen N*
 Kristine Faerch, *Gentofte*
 Louise G Grunnet, *Gentofte*
 R Scott Heller, *Gentofte*
 Filip K Knop, *Hellerup*
 Helle Markholst, *Måløv*
 Ole H Mortensen, *Copenhagen N*
 Oluf Pedersen, *Copenhagen K*
 Esben T Vestergaard, *Aarhus N*
 Milan Zdravkovic, *Soborg*



Egypt

Mamdouh MA Hssan, *Dokki*
 Moshira AH Rateb, *Cairo*
 Mona F Schaalán, *Cairo*



Finland

Siamak Bidel, *Helsinki*
 Gang Hu, *Helsinki*
 Thomas Kietzmann, *Oulu*
 Qing Qiao, *Espoo*
 Karoliina Wehkalampi, *Helsinki*



France

Jean C Ansquer, *Dijon*
 Bertrand Cariou, *Nantes*
 Sylvie Dejager, *Rueil-Malmaison*
 Naim A Khan, *Dijon*
 Jean-Philippe Lavigne, *Nimes*
 Michel Marre, *Paris*
 Marie-Claude Morice, *Massy*
 Riccardo Perfetti, *Paris*
 Gérard Said, *Paris*
 Didier Vieau, *Villeneuve*
 Sophie Visvikis-Siest, *Nancy*



Germany

Christa Buechler, *Regensburg*
 Roland Büttner, *Heidelberg*
 Michael Froehner, *Dresden*
 Ioanna Gouni-Berthold, *Cologne*
 Hammes Hans-Peter, *Mannheim*
 Nadja Herbach, *Munich*
 Nadj Herbach, *München*
 Andrea Icks, *Düsseldorf*
 Thomas Jax, *Neuss*
 Michael Kluge, *Munich*
 Florian Lang, *Tuebingen*

Matthias Laudes, *Koln*
 Ralf Lobmann, *Stuttgart*
 Rafael T Mikolajczyk, *Bremen*
 Andreas S Mueller, *Halle*
 Karsten Müssig, *Tübingen*
 Nahid Parvizi, *Mariensee*
 Thomas P Reinehr, *Datteln*
 Michael Ristow, *Jena*
 Sven Schinner, *Duesseldorf*
 Peter EH Schwarz, *Dresden*
 Ovidiu A Stirban, *Oeynhausen*
 Diego J Walther, *Berlin*
 Silvia A Wein, *Kiel*
 Christian Wrede, *Berlin*
 Dan Ziegler, *Düsseldorf*



Greece

George P Chrousos, *Athens*
 Moses S Elisaf, *Ioannina*
 Panagiotis Georgoulas, *Larissa*
 Nikolaos Kadoglou, *Thessaloniki*
 Gerasimos E Krassas, *Krini*
 Spilios Manolakopoulos, *Athens*
 Peppa Melpomeni, *HalDari*
 Nikolaos Papanas, *Alexandroupolis*
 Dimitrios Papazoglou, *Alexandroupolis*
 Sokratis Pastromas, *Athens*
 Christina Piperi, *Goudi*
 Nicholas K Tentolouris, *Athens*
 Konstantinos A Toulis, *Salonika*
 Apostolos Tsapas, *Thessaloniki*
 Konstantinos Tziomalos, *Thessaloniki*
 Elias Zintzaras, *Larissa*



Hungary

Mária Bagyánszki, *Szeged*
 Gyorgy Jermendy, *Budapest*
 Karoly Racz, *Budapest*
 Gyula Soltesz, *Pécs*



Iceland

Saher Hamed, *Haifa*



India

Sarika Arora, *New Delhi*
 Pitchai Balakumar, *Sivakasi*
 Muthuswamy Balasubramanyam, *Chennai*
 Anuradha Carani Venkatraman, *Nagar*
 Subhabrata Chakrabarti, *Hyderabad*
 Abhay S Chakraborti, *Kolkata*
 Tapan K Chaudhuri, *New Delhi*
 Kanwaljit Chopra, *Chandigarh*
 Malabika Datta, *Delhi*
 Debidas Ghosh, *West Bengal*
 Ravinder Goswami, *New Delhi*
 Jothydev Kesavadev, *Kerala*
 KVS H Kumar, *Lucknow*

Anoop Misra, *New Delhi*
 Analava Mitra, *Kharagpur*
 Viswanathan Mohan, *Chennai*
 Pallavi Panchu, *Bangalore*
 Deepak N Patel, *Mumbai*
 Usharani Pingali, *Hyderabad*
 Ambady Ramachandran, *Chennai*
 Vadde Ramakrishna, *Kadapa*
 Rajat Sandhir, *Chandigarh*
 Manju Sharma, *New Delhi*
 Suman B Sharma, *Delhi*



Iran

Mohammad K Arababadi, *Rafsanjan*
 Leila Azadbakht, *Isfahan*
 Hamid Baradaran, *Tehran*
 Behrooz Broumand, *Tehran*
 Majid Ghayour-Mobarhan, *Mashhad*
 Mohsen Janghorbani, *Isfahan*



Iraq

Saad AR Hussain, *Baghdad*
 Abbas A Mansour, *Basrah*



Ireland

Amar Agha, *Dublin*
 Michael Aviram, *Haifa*
 Raymond E Farah, *Safed*
 Mark P Hehir, *Dublin*



Israel

Gal Dubnov-Raz, *Hashomer*
 Shimon Efrat, *Tel Aviv*
 Oren Froy, *Rehovot*
 Farid M Nakhoul, *Lower Galilee*
 Orit Pinhas-Hamiel, *Ramat-Gan*
 Eleazar Shafir, *Jerusalem*
 Gerald H Tomkin, *Dublin*
 Haim Werner, *Tel Aviv*
 Marina S Zimlichman, *Holon*



Italy

Luigi A Angrisani, *Napoli*
 Roberto Baldelli, *Rome*
 Giuseppe Barbaro, *Rome*
 Alessandro Bartolomucci, *Parma*
 Giuseppina Basta, *Pisa*
 Simona Bertoli, *Milano*
 Federico Bilotta, *Rome*
 Fabio Broglio, *Torino*
 Riccardo Calafiore, *Perugia*
 Sergio Coccheri, *Bologna*
 Massimo Collino, *Torino*
 Marco A Comaschi, *Genoa*
 Renzo Cordera, *Genova*
 Francesco Dotta, *Siena*

Fiorucci Fiorucci, *Perugia*
 Maurizio Galderisi, *Naples*
 Amalia Gastaldelli, *Pisa*
 Ezio Ghigo, *Turin*
 Carla Giordano, *Palermo*
 Paolo Gisondi, *Verona*
 Riccarda Granata, *Turin*
 Giorgio Iervasi, *Pisa*
 Claudia Kusmic, *Pisa*
 Francesco Landi, *Rome*
 Monica R Loizzo, *Cosenza*
 Paolo Magni, *Milan*
 Mariano Malaguarnera, *Catania*
 Melania Manco, *Rome*
 Giulio M Marchesini, *Bologna*
 Piero Marchetti, *Pisa*
 Massimo Massi-Benedetti, *Perugia*
 Moschetta Moschetta, *Bari*
 Antonio E Nicolucci, *Milano*
 Lucia Pacifico, *Rome*
 Stefano Palomba, *Reggio Emilia*
 Giampaolo Papi, *Carpi*
 Renato Pasquali, *Bologna*
 Piermarco M Piatti, *Milano*
 Dario Pitocco, *Rome*
 Antonio E Pontiroli, *Milano*
 Manfredi Rizzo, *Palermo*
 Carmelo L Rosa, *Catania*
 Raffaella Rosso, *Genoa*
 Giuseppe Schillaci, *Perugia*
 Leonardo A Sechi, *Sassari*
 Imad Sheiban, *Verona*
 Cesare R Sirtori, *Milano*
 Giovanni Tarantino, *Naples*
 Giovanni Targher, *Verona*
 Francesco G Tieh, *Chieti*
 Donadon Valter, *Pordenone*
 Alberto Verrotti, *Chieti*
 Andrea Viggiano, *Napoli*
 Gian V Zuccotti, *Milan*



Japan

Masato Asahina, *Chiba*
 Takuya Awata, *Tochigi*
 Yuichiro Eguchi, *Saga*
 Goji Hasegawa, *Kyoto*
 Satoshi Inoue, *Tokyo*
 Eiji Ishimura, *Osaka*
 Masayuki Iwano, *Nara*
 Takashi Kadowaki, *Tokyo*
 Eisuke Kagawa, *Hiroshima*
 Masahito Katahira, *Nagoya*
 Eiji N Kawasaki, *Nagasaki*
 Noriyuki Koibuchi, *Gunma*
 Kazuhiko Kotani, *Tochigi*
 Daisuke Koya, *Ishikawa*
 Norikazu Maeda, *Osaka*
 Takayuki Masaki, *Oita*
 Yuji Matsuzawa, *Osaka*
 Kazuaki Nishio, *Tokyo*
 Kenji Okumura, *Nagoya*
 Motoaki Saito, *Yonago*
 Toshiyasu Sasaoka, *Toyama*

Michio Shimabukuro, *Okinawa*
 Kohzo Takebayashi, *Saitama*
 Hiroyuki Tamemoto, *Abiko*
 Takashi Togo, *Yokohama*
 Jun Udagawa, *Izumo*
 Yoshinari Uehara, *Fukuoka*
 Takuya Watanabe, *Tokyo*
 Toshihiko Yada, *Tochigi*
 Tohru Yorifuji, *Kyoto*



Jordan

Yousef S Khader, *Irbid*



Kuwait

Kamal AAS Al-Shoumer, *Surra*
 Ibrahim F Benter, *Safat*
 Abu S Mustafa, *Safat*



Lebanon

Ramzi F Sabra, *Beirut*



Malaysia

Mafauzy Mohamed, *Kota Bharu*



Malta

Charles Savona-Ventura, *Msida*



Mexico

Manuel Gonzalez-Ortiz, *Guadalajara*
 Fernando Guerrero-Romero, *Dgo*
 Jesus A Olivares-Reyes, *Mexico*
 Rocío Salceda, *Mexico*



Netherlands

Sander Kersten, *Wageningen*
 Nanne Kleefstra, *Zwolle*
 Edwin CM Mariman, *Maastricht*
 Frans Pouwer, *Tilburg*
 Han Roelofsen, *Groningen*
 Suat Simsek, *Alkmaar*
 Marcel T Twickler, *Halsterseweg*



New Zealand

Paul Hofman, *Auckland*
 Peter E Lobie, *Grafton*
 Elaine Rush, *Auckland*



Nigeria

Adejuwon A Adeneye, *Ikeja*
 Anthonia O Ogbera, *Ikeja*

**Norway**

Akhtar Hussain, *Oslo*
Odd E Johansen, *Hovik*

**Oman**

Jumana S Saleh, *Muscat*
Mohammed A Shafae, *Muscat*
Radha Shenoy, *Muscat*

**Pakistan**

Shahid Hameed, *Islamabad*
Jamil A Malik, *Islamabad*

**Poland**

Marcin Baranowski, *Bialystok*
Jerzy Beltowski, *Lublin*
Alicia H Dydejczyk, *Krakow*
Maciej Owecki, *Poznań*
Ewa Pankowska, *Warsaw*
Agnieszka Piwowar, *Wroclaw*
Dorota A Zieba, *Krakow*

**Portugal**

Graca M Pereira, *Braga*

**Qatar**

Hong Ding, *Doha*

**Romania**

Elena Ganea, *Bucharest*
Adriana Georgescu, *Bucharest*

**Singapore**

Thameem T Dheen, *Singapore*
Yung-Seng Lee, *Singapore*
Daniel PK Ng, *Singapore*
Rob M van Dam, *Singapore*

**Slovakia**

Katarína Šebeková, *Bratislava*

**South Africa**

Md S Islam, *Durban*

**South Korea**

Hueng-Sik Choi, *Gwangju*

Kyung M Choi, *Seoul*
Won M Hwang, *Seoul*
Eui-Bae Jeung, *Cheongju*
Ju-Hee Kang, *Incheon*
Sin-Gon Kim, *Seongbuk-Gu*
Sung-Jin Kim, *Seoul*
Young-Gyu Ko, *Seoul*
Kang-Beom Kwon, *Chonbuk*
Sangyeoup Lee, *Yangsan*
Myung Gull Lee, *Gyeonggi-Do*
Soo Lim, *Seongnam*
Byung-Hyun Park, *Jeonbuk*
Seungjoon Park, *Seoul*
Jeesuk Yu, *Chungnam*

**Spain**

Vivencio Barrios, *Madrid*
M. Luisa Bonet, *Palma de Mallorca*
Justo P Castano, *Cordoba*
Manuel A Diosdado, *Cádiz*
Javier Espino, *Badajoz*
Ricardo V García-Mayor, *Vigo*
José M Gómez-Sáez, *Barcelona*
Oreste Gualillo, *Santiago de Compostela*
Emilio Herrera, *Madrid*
Amelia Marti, *Pamplona*
Navarra JA Martínez, *Pamplona*
Maria L Martinez-Chantar, *Derio*
Merce Miranda, *Tarragona*
Alberto Ortiz, *Madrid*
Maria J Ramirez, *Pamplona*
Eugenia Resmini, *Barcelona*
Pedro Romero-Aroca, *Reus*
Jordi Salas-Salvado, *Reus*
Gines M Salido, *Caceres*
Victor Sanchez-Margalet, *Seville*
Helmut Schroder, *Barcelona*
Carmen Segundo, *Cádiz*
Rafael Simo, *Barcelona*
Manuel Vazquez-Carrera, *Barcelona*

**Sweden**

Joanna Hlebowicz, *Malmö*
Peter Lindgren, *Stockholm*
Kaj S Stenlof, *Göteborg*
Ann-Britt Wirehn, *Linköping*
Wei-Li Xu, *Stockholm*
Shao-Nian Yang, *Stockholm*

**Switzerland**

Kaspar Berneis, *Zurich*
Kim-Anne Le, *Lausanne*
Christian Toso, *Geneva*

**Thailand**

Narattaphol Charoenphandhu, *Bangkok*
Arthorn Riewpaiboon, *Bangkok*

Rawee Teanpaisan, *Hat-Yai*
Viroj Wiwanitkit, *Bangkok*

**Tunisia**

Khaled Hamden, *Sfax*

**Turkey**

Ugur Cavlak, *Denizli*
Teoman Dogru, *Etilik*
Ersin Fadillioglu, *Ankara*
Abdurrahman F Fidan, *Afyonkarahisar*
Muammer Karadeniz, *Bornova-Izmir*
Cevde Kaya, *Istanbul*
Fahrettin Kelestimur, *Kayseri*
Altan Onat, *Istanbul*
Semir Ozdemir, *Antalya*
Mustafa Sahin, *Ankara*
Ilker Tasci, *Ankara*
Belma Turan, *Ankara*
Serap Yalin, *Mersin*

**United Arab Emirates**

Ernest Akingunola Adeghate, *Al Ain*
Mukesh M Agarwal, *Al Ain*
Samir M Awadallah, *Sharjah*

**United Kingdom**

Nisreen Alwan, *Leeds*
Bing Chen, *Liverpool*
Fay Crawford, *Edinburgh*
Timothy M Curtis, *Belfast*
Umesh Dashora, *Edinburgh*
Gareth W Davison, *Belfast*
Peter Flatt, *Coleraine*
Kathleen M Gillespie, *Bristol*
Peter J Grant, *Leeds*
Lorna W Harries, *Exeter*
Nigel Hoggard, *Aberdeen*
Nigel Irwin, *Coleraine*
Pappachan Joseph, *London*
Andreas F Kolb, *Aberdeen*
Moffat J Nyirenda, *Edinburgh*
Jeetesh V Patel, *Birmingham*
Snorri B Rafnsson, *Edinburgh*
Thozhukat Sathyapalan, *Yorkshire*
Latika Sibal, *Newcastle*
Rajagopalan Sriraman, *Lincoln*
Ramasamyiyer Swaminathan, *London*
Abd A Tahrani, *Birmingham*
Neil G Thomas, *Birmingham*
Cecil Thompson, *London*
Paul H Whiting, *Leicester*

**United States**

Varun Agrawal, *Springfield*

Pascale Alard, *Louisville*
 Omar Ali, *Milwaukee*
 Mohamed AS Al-Shabrawey, *Augusta*
 Judith Aponte, *New York*
 Balamurugan N Appakalai, *Louisville*
 Hwyla A Arafat, *Philadelphia*
 Carl V Asche, *Salt Lake City*
 Sanford A Asher, *Pittsburgh*
 Anthony Atala, *Winston-Salem*
 Sami T Azar, *New York*
 George L Bakris, *Chicago*
 Alistair J Barber, *Hershey*
 Daniel C Batlle, *Chicago*
 David SH Bell, *Birmingham*
 Rita Bortell, *Worcester*
 Sebastien G Bouret, *Los Angeles*
 Donald W Bowden, *Winston-Salem*
 David L Brown, *Stony Brook*
 Jack D Caldwell, *Erie*
 Anna C Calkin, *Los Angeles*
 Roberto A Calle, *Groton*
 Keith R Campbell, *Pullman*
 Carlos Campos, *New Braunfels*
 Heping Cao, *New Orleans*
 Krista Casazza, *Birmingham*
 Aaron B Caughey, *Portland*
 Eileen R Chasens, *Pittsburgh*
 Munmun Chattopadhyay, *Ann Arbor*
 Xiao-Li Chen, *St Paul*
 Craig I Coleman, *Hartford*
 Robert Conley, *Indianapolis*
 Colleen Croniger, *Cleveland*
 Doyle M Cummings, *Greenville*
 William C Cushman, *Memphis*
 Patricia Darbishire, *West Lafayette*
 Guillaume Darrasse-Jeze, *New York*
 Ravi KM Dasu, *Sacramento*
 Michael H Davidson, *Chicago*
 Prakash Deedwania, *San Francisco*
 Hong-Wen Deng, *Kansas City*
 Teresa P DiLorenzo, *Bronx*
 Scot Dowd, *Lubbock*
 Samuel Durso, *Baltimore*
 Krystal Edwards, *Dallas*
 Alexander M Efanov, *Indianapolis*
 Azza B El-Remessy, *Augusta*
 Amy Z Fan, *Atlanta*
 Melissa S Faulkner, *Tucson*
 George S Ferzli, *Staten Island*
 Paolo Fiorina, *Boston*
 James E Foley, *East Hanover*
 Samuel N Forjuoh, *Temple*
 Alessia Fornoni, *Miami*
 Trudy Gaillard, *Columbus*
 Pietro Galassetti, *Irvine*
 Claudia Gagnoli, *Hershey*
 Jennifer B Green, *Durham*
 Alok K Gupta, *Piscataway*
 Gary J Grover, *Piscataway*
 Werner Gurr, *New Haven*
 Samy L Habib, *San Antonio*
 Abdel Hamad, *Baltimore*
 Tiffany Hilton, *Pittsford*

Michael F Holick, *Boston*
 Zhaoyong Hu, *Houston*
 Rachel Hudacko, *Suffern*
 Yasuo Ido, *Boston*
 Brian K Irons, *Lubbock*
 Pamela Itkin-Ansari, *La Jolla*
 Hieronim Jakubowski, *Newark*
 Hong-Lin Jiang, *Blacksburg*
 Ping Jiao, *Providence*
 Shengkan Jin, *Piscataway*
 Arpita Kalla, *St Louis*
 Richard E Katholi, *Springfield*
 Melina R Kibbe, *Chicago*
 Bhumsoo Kim, *Ann Arbor*
 Tomoshige Kino, *Bethesda*
 Julienne K Kirk, *Winston-Salem*
 Renu A Kowluru, *Detroit*
 Lewis H Kuller, *Pittsburgh*
 Rajesh Kumar, *Temple*
 Blandine Laferriere, *New York*
 Cong-Jun Li, *Beltsville*
 Ching-Shwun Lin, *San Francisco*
 James F List, *Princeton*
 Dongmin Liu, *Blacksburg*
 Zhen-Qi Liu, *Charlottesville*
 Maria F Lopes-Virella, *Charleston*
 Cai Lu, *Louisville*
 George W Lyerly Jr, *Conway*
 Jian-Xing Ma, *Oklahoma City*
 Xin-Laing Ma, *Philadelphia*
 Rong Ma, *Fort Worth*
 David Maggs, *San Diego*
 Kenneth Maiese, *Newark*
 Kevin C Maki, *Glen Ellyn*
 Sridhar Mani, *Bronx*
 Suresh Mathews, *Auburn*
 Lauraar R McCabe, *East Lansing*
 Sarah Messiah, *Miami*
 Thomas O Metz, *Richland*
 Shannon Miller, *Orlando*
 Murielle Mimeault, *Omaha*
 Raghu G Mirmira, *Indianapolis*
 Prasun J Mishra, *Bethesda*
 Reema Mody, *Grayslake*
 Arshag D Mooradian, *Jacksonville*
 Mohammad-Reza Movahed, *Tucson*
 Yingjun J Mu, *Rahway*
 Nair G Muraleedharan, *East Lansing*
 Manuel F Navedo, *Seattle*
 Charles B Nemeroff, *Atlanta*
 Joshua J Neumiller, *Spokane*
 Steven J Nicholls, *Cleveland*
 Hirofumi Noguchi, *Dallas*
 Craig S Nunemaker, *Charlottesville*
 Patrick J O'Connor, *Minneapolis*
 Wei-Hong Pan, *Baton Rouge*
 Naushira Pandya, *Fort Lauderdale*
 Michael R Peluso, *Corvallis*
 Inga Peter, *New York*
 Axel Pflueger, *Rochester*
 Gretchen A Piatt, *Pittsburgh*
 John D Piette, *Ann Arbor*

Leonid Poretsky, *New York*
 Parviz M Pour, *Omaha*
 Wei Qiu, *Boston*
 Teresa Quattrin, *Buffalo*
 Cristina Rabadán-Diehl, *Bethesda*
 Rajendra S Raghov, *Memphis*
 Swapnil N Rajpathak, *Bronx*
 Armin Rashidi, *Norfolk*
 Mohammed S Razzaque, *Boston*
 Beverly AS Reyes, *Philadelphia*
 Shuo L Rios, *Los Angeles*
 David Rodbard, *Potomac*
 Helena W Rodbard, *Rockville*
 June H Romeo, *Cleveland*
 Raul J Rosenthal, *Florida*
 Juan M Saavedra, *Bethesda*
 Frank AJL Scheer, *Boston*
 Richard E Scranton, *Tiverton*
 Vallabh R Shah, *Albuquerque*
 Aziz Shaibani, *Houston*
 Guo-Ping Shi, *Boston*
 Carol A Shively, *Winston-Salem*
 Anders AF Sima, *Detroit*
 Rajan Singh, *Los Angeles*
 Pramil N Singh, *Loma Linda*
 Dawn D Smiley, *Atlanta*
 Matthew D Solomon, *Stanford*
 Rakesh K Srivastava, *Tyler*
 Bangyan L Stiles, *Los Angeles*
 Erin St Onge, *Apopka*
 Yu-Xiang Sun, *Houston*
 Salim Surani, *Corpus Christi*
 Arthur LM Swislocki, *Martinez*
 Ya-Xiong Tao, *Auburn*
 John A Tayek, *Torrance*
 John G Teeter, *New Haven*
 Carlos M Telleria, *Vermillion*
 Christophe G Thanos, *Providence*
 Ronald G Tilton, *Galveston*
 Serena Tonstad, *Loma Linda*
 Michael Traub, *Staten Island*
 Margrit Urbanek, *Chicago*
 Vladimir N Uversky, *Indianapolis*
 Gabriel Uwaifo, *Baton Rouge*
 Volker Vallon, *San Diego*
 Shambhu D Varma, *Baltimore*
 Chengming Wang, *Auburn*
 Hong-Jun Wang, *Boston*
 Mark E Williams, *Boston*
 Guang-Yu Wu, *New Orleans*
 Zhong-Jian Xie, *San Francisco*
 Ming-Zhao Xing, *Baltimore*
 Hariom Yadav, *Bethesda*
 Lijun Yang, *Gainesville*
 Ruoqing Yang, *Rahway*
 Subhashini Yaturu, *Albany*
 Joseph Yeboah, *Charlottesville*
 Dengping Yin, *Nashville*
 Yi-Sang Yoon, *Rochester*
 Yi-Hao Yu, *New York*
 Kevin CJ Yuen, *Portland*
 Ian S Zagon, *Hershey*

Robert YL Zee, *Boston*
Cui-Lin Zhang, *Rockville*
James X Zhang, *Richmond*
Sarah X Zhang, *Oklahoma City*
Guixiang Zhao, *Atlanta*
Yang Zhao, *Carmel*

Ming-Hui Zou, *Oklahoma City*



Venezuela

José F Arévalo, *San Bernardino*

Fuad Lechin, *Caracas*



Yemen

Khaled AA Ahmed, *Ibb*

**REVIEW**

- 165 Diabetes epidemic sweeping the Arab world
Abuyassin B, Laher I

LETTERS TO THE EDITOR

- 175 Comment on: Statin use and risk of diabetes mellitus
Eren MA, Sabuncu T, Karaaslan H

Contents

World Journal of Diabetes
Volume 7 Number 8 April 25, 2016

ABOUT COVER

Editorial Board Member of *World Journal of Diabetes*, José M Gómez-Sáez, MD, PhD, Research Fellow, Endocrinology Service, Hospital Universitario de Bellvitg, 08907 Barcelona, Spain

AIM AND SCOPE

World Journal of Diabetes (*World J Diabetes*, *WJD*, online ISSN 1948-9358, DOI: 10.4239), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJD covers topics concerning α , β , δ and PP cells of the pancreatic islet, the effect of insulin and insulinresistance, pancreatic islet transplantation, adipose cells and obesity.

We encourage authors to submit their manuscripts to *WJD*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ ABSTRACTING

World Journal of Diabetes is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, and PubMed Central.

FLYLEAF

I-VI Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Su-Qing Liu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Fang-Fang Ji*
Proofing Editorial Office Director: *Xiu-Xia Song*

NAME OF JOURNAL

World Journal of Diabetes

ISSN

ISSN 1948-9358 (online)

LAUNCH DATE

March 15, 2010

FREQUENCY

Biweekly

EDITORS-IN-CHIEF

Lu Qi, MD, PhD, Assistant Professor, Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave., Boston, MA 02115, United States

Jingbo Zhao, PhD, Associate Professor, Aalborg Hospital Science and Innovation Centre, Aalborg Hospital, Aarhus University Hospital, Aalborg 9000, Denmark

EDITORIAL OFFICE

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

World Journal of Diabetes

Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-85381891

Fax: +86-10-85381893

E-mail: editorialoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc

8226 Regency Drive,

Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

PUBLICATION DATE

April 25, 2016

COPYRIGHT

© 2016 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/bpg/g_info_20160116143427.htm

ONLINE SUBMISSION

<http://www.wjgnet.com/esps/>

Diabetes epidemic sweeping the Arab world

Bisher Abuyassin, Ismail Laher

Bisher Abuyassin, Ismail Laher, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada

Author contributions: Abuyassin B conducted the literature search and prepared the manuscript; Laher I reviewed and edited the manuscript.

Conflict-of-interest statement: Authors have no financial conflicts of interest related to this work.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Dr. Ismail Laher, PhD, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, 2176 Health Science Mall, Medical Block C, Vancouver, BC V6T 1Z3, Canada. ilaher@mail.ubc.ca
Telephone: +1-604-8225882
Fax: +1-604-8226012

Received: December 16, 2015
Peer-review started: December 18, 2015
First decision: January 18, 2016
Revised: January 27, 2016
Accepted: February 16, 2016
Article in press: February 17, 2016
Published online: April 25, 2016

Abstract

The prevalence of type-2 diabetes mellitus (T2DM) has increased dramatically during the last 2 decades, a fact driven by the increased prevalence of obesity, the primary risk factor for T2DM. The figures for diabetes in the Arab world are particularly startling as the number of people with diabetes is projected to increase by 96.2%

by 2035. Genetic risk factors may play a crucial role in this uncontrolled rise in the prevalence of T2DM in the Middle Eastern region. However, factors such as obesity, rapid urbanization and lack of exercise are other key determinants of this rapid increase in the rate of T2DM in the Arab world. The unavailability of an effective program to defeat T2DM has serious consequences on the increasing rise of this disease, where available data indicates an unusually high prevalence of T2DM in Arabian children less than 18 years old. Living with T2DM is problematic as well, since T2DM has become the 5th leading cause of disability, which was ranked 10th as recently as 1990. Giving the current status of T2DM in the Arab world, a collaborative international effort is needed for fighting further spread of this disease.

Key words: Diabetes; Arab world; Epidemiology; Etiology; Risk factors and complication

© **The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The Middle Eastern and North African region has the second highest rate of increases in diabetes anywhere in the world. We comprehensively review type-2 diabetes mellitus (T2DM) in adults and children from 22 Arab speaking countries by reviewing data published from 1980 to 2015; this allowed us to have a better view of the trends in the dramatic increases of T2DM impacting the Arabic region. We also discuss the etiology of this uncontrolled medical crisis and the most commonly reported complications in these Arab speaking countries. Finally, we highlight a number of crucial data that appear to be unavailable but which may be essential for a more comprehensive understanding of the diabetes epidemic sweeping the Arabian region.

Abuyassin B, Laher I. Diabetes epidemic sweeping the Arab world. *World J Diabetes* 2016; 7(8): 165-174 Available from: URL: <http://www.wjgnet.com/1948-9358/full/v7/i8/165.htm>
DOI: <http://dx.doi.org/10.4239/wjd.v7.i8.165>

INTRODUCTION

Diabetes mellitus (DM) affects more than 382 million people around the world, of whom 90% are diagnosed with type-2 DM (T2DM)^[1]. The prevalence of T2DM has increased dramatically during the last 2 decades^[1]. The Arab world is not immune from this epidemic in the prevalence of T2DM. In fact, the Middle Eastern and North African region has the second highest rate of increase in diabetes globally, with the number of people with diabetes is projected to increase by 96.2% in 2035^[1]. Having T2DM increases the burden for both patients and their caregivers, and of particular concern for Arab governments is the large economic burden of diabetes in terms of cost of treatment, management of complications, disability and loss of productivity^[2-4]. The factors associated with T2DM seem more pronounced in the Arab world. Although genetic risk factors can't be ruled out in the context of T2DM in the Arab world, factors such as obesity, rapid urbanization and lack of exercise are key determinants of the rapid increase of the rate of T2DM among the Arab world^[5].

The unavailability of an effective program to contain the dramatic rise in T2DM in the Arab world has led to a serious development in the disease's course, where current data indicates that T2DM can't be ruled out in children less than 18 years old. Children diagnosed with T2DM come from all countries in the Arab world and obesity is a hallmark feature in this age group^[6,7].

This review will initially address the epidemiology of T2DM in the Arab world, followed by the etiology of the disease, complication and risk factors of T2DM, and finally will discuss some suggestions related to research on T2DM in the Arab world.

RESEARCH METHODS

We undertook a search of the medical literature using the PubMed, EMBASE and Ovid databases for articles published in English language between 1980 and 2015, and included the following keywords: Diabetes, Arab world, epidemiology, etiology, risk factors and complication, or their corresponding MeSH term synonyms. Among 22 Arabic countries, a total of 2347 papers were identified and screened by title and/or abstract (Figure 1). To ensure that we included the highest number of epidemiological studies from each country, we did not set any limitations on the study design in our exclusion criteria. However, animal or genetic studies, studies not relevant to T2DM, studies on the effects of treatment, and non-primary data such as review articles or adherence studies were excluded (Figure 2). A total of 85 studies were added in the article and were reviewed in full. Among these, 3 studies were concerning Arab immigrants in different countries not listed in Figure 1, and 1 study (not PubMed indexed) was obtained from the references of other paper.

EPIDEMIOLOGY

Adults

Based on the International Diabetes Federation (IDF) estimates from 2013^[1], three countries from the Arabic world are among the top 10 countries worldwide for the prevalence of T2DM; these countries are Saudi Arabia, Kuwait and Qatar. The data obtained from each country in the Arabic world reports variation regarding prevalence of T2DM. However, differences in reported prevalence of T2DM within each country can be attributed to the study design, population and diagnostic methods used to obtain these data. The data clearly confirms that the prevalence of T2DM has increased dramatically during the past two decades. For example, studies from Saudi Arabia in the 80's indicated that prevalence of T2DM was between 2.4%-4.3%^[8,9], while recent a study in Saudi Arabia indicated a dramatic increase in the rate of T2DM with an estimated prevalence of 25.4%^[10]. This pattern of massive increases in the rate of T2DM is similar for Iraq, Oman and other countries within the Arabic world (Table 1).

Children and adolescents

Due to the recent recognition of T2DM during childhood, limited data are available worldwide. This unusual age-related disease has become a focus of attention for medical organizations around the world. A recent analysis showed a significant increase of 30.5% in the prevalence of T2DM among children and adolescents aged 10-19 years old in United States from 2001 to 2009^[11]. The international society for pediatric and adolescents diabetes has published comprehensive guidelines for screening, diagnosis and treatment of T2DM in children and adolescents^[12].

Not surprisingly, data from the Arab world show similar figures for childhood T2DM. Perhaps more worrying is that recent data from Saudi Arabia reports an age-specific prevalence of 1 per 1000 for T2DM in children less than 18 years old^[7], which was similar to the highest prevalence found in specific groups (American Indian and African American) in United States^[12]. Additional findings on childhood T2DM are summarized in Table 2.

RISK FACTORS

A number of risk factors could account for the uncontrolled rise in T2DM in the Arab world, with genetic factors likely to play an important role. However, a number of modifiable risk factors such as obesity, rapid urbanization and its associated changes in dietary habits and lack of physical activity are also important determinants in the etiology of T2DM. Other considerations such as multiple pregnancies and a lack of health education may be unique challenges in the diabetes epidemic in the Arab world.




Figure 1 Number of studies reviewed by title and/or abstract for each Arabic country.




Figure 2 Research scheme and exclusion criteria. T2DM: Type-2 diabetes mellitus; T1DM: Type-1 diabetes mellitus.

Obesity

Obesity represent a large component in the pathogenesis of T2DM^[13], and is by far the primary risk factor for the

increased prevalence of T2DM globally^[14]. Obesity not only worsens the prognosis of T2DM, but obese diabetics suffer higher rates of microvascular complications and mortality^[15-18]. Obesity-related T2DM has been investigated in several countries in the Arab world. In Saudi Arabia, a study of 14252 diabetic patients reported that more than half of the obese diabetics had poor glycemic control^[19]. Additionally, the first national health survey in Kuwait indicates that 48% obese males and 77% obese females were also diabetics^[20], confirming a significant association between obesity and diabetes [odds ratio (OR) of 2.87] in the Kuwaiti population. In Oman and Qatar, 60.1% and 59.7% of the diabetic patients were obese respectively^[21,22]. The average body mass index (BMI) in Palestinian and Lebanese diabetics was 33.7 kg/m² and 30.8 kg/m² respectively^[23,24]. Nevertheless, obesity is significantly associated with diabetes even in some Arab countries such as Sudan and Tunisia where the prevalence of diabetes can be described as relatively low - the relative risk of developing T2DM was 1.74 (95%CI: 1.32-2.28) in obese Sudanese subjects and the OR of having T2DM was 1.61 (95%CI: 1.34-1.93) in obese Tunisians^[25,26].

A recent analysis of 46 Muslim countries (where Muslims represent > 50% of the population) estimated the prevalence of overweight subjects reported that in the Eastern Mediterranean region, females were more likely to be overweight than males (42.1% vs 33%)^[27]. Interestingly, those living in Arab countries were 2.92 (95%CI: 2.86-2.97) times more likely to be overweight compared to those living in non-Arab Muslim countries.

Rapid urbanization

Urbanizing of many rural areas within the Arab world carries with it many advantages in term of access to

Table 1 Prevalence of type-2 diabetes mellitus in adult Arab population

Ref.	Country	Year	Sample size	Main findings	Diagnostic technique
Bacchus <i>et al</i> ^[8]	Saudi Arabia	1982	1385	Prevalence of diabetes: 2.4%	WHO criteria
Fatani <i>et al</i> ^[9]	Saudi Arabia	1987	5222	Prevalence of diabetes: 4.3%	Random capillary blood glucose
Al-Nuaim <i>et al</i> ^[28]	Saudi Arabia	1997	13177	Prevalence of diabetes in urban males and females: 12%, 14% Prevalence of diabetes in rural males and females: 7%, 7.7%	Random plasma glucose
Rahman Al-Nuaim <i>et al</i> ^[47]	Saudi Arabia	1997	2059	Prevalence of T2DM in obese males: 26.0% Prevalence of T2DM in non-obese males: 8.6% ($P < 0.001$) Prevalence of T2DM in obese females: 23.5% Prevalence of T2DM in non-obese females: 4.4% ($P < 0.0001$)	OGTT
el-Hazmi <i>et al</i> ^[48]	Saudi Arabia	2000	14660	Prevalence of obesity in males: 13.05% Prevalence of obesity in females: 20.26% Prevalence of obesity in diabetics: 29.98% Prevalence of obesity in non-diabetics: 15.87% ($P < 0.0001$)	FBG
Al-Nozha <i>et al</i> ^[49]	Saudi Arabia	2004	16917	Prevalence of diabetes: 23.7%	FPG
Almajwal <i>et al</i> ^[50]	Saudi Arabia	2009	195851	Prevalence of diabetes: 17.2%	FBG
Al-Rubeaan <i>et al</i> ^[10]	Saudi Arabia	2014	18034	Prevalence of diabetes: 25.4%	FPG
Al-Rubeaan <i>et al</i> ^[51]	Saudi Arabia	2014	53370	Prevalence of abnormal glucose metabolism: 34.5%	FPG
El Bcheraoui <i>et al</i> ^[52]	Saudi Arabia	2014	10735	Prevalence of diabetes: 13.4%	FPG
Abdella <i>et al</i> ^[53]	Kuwait	1996	8336	Prevalence of diabetes: 7.6%	Medical chart review
Al Khalaf <i>et al</i> ^[54]	Kuwait	2010	560	Prevalence of diabetes: 21.4%	FBG
Alarouj <i>et al</i> ^[20]	Kuwait	2013	1970	Prevalence of diabetes: 17.9%	FPG
Al Zurba <i>et al</i> ^[55]	Bahrain	1996	498	Prevalence of diabetes: 25.5%	FPG
Malik <i>et al</i> ^[56]	UAE	2005	5758	Prevalence of T2DM: 20.2%	FPG
Saadi <i>et al</i> ^[57]	UAE	2007	2455	Prevalence of diagnosed T2DM: 10.5% Prevalence of undiagnosed T2DM: 6.6%	FBG
Mansour <i>et al</i> ^[58]	Iraq	2007	13730	Incidence of T2DM: 6.8%	FPG
Mansour <i>et al</i> ^[59]	Iraq	2014	5445	Prevalence of T2DM: 19.7%	FPG
Al-Moosa <i>et al</i> ^[21]	Oman	2006	5840	Prevalence of T2DM: 11.6%	FPG
Al-Lawati <i>et al</i> ^[60]	Oman	2015	NA	Age-adjusted prevalence of T2DM: 10.4% to 21.1%	FPG and OGTT
Musaiger <i>et al</i> ^[61]	Qatar	2005	535	Prevalence of T2DM among obese females ≥ 50 yr: 51.4%	Self-reported diabetes
Bener <i>et al</i> ^[22]	Qatar	2009	1117	Prevalence of T2DM: 16.7%	FBG and OGTT
Al-Habori <i>et al</i> ^[62]	Yemen	2004	498	Prevalence of T2DM: 7.4%	FPG
Gunaid <i>et al</i> ^[63]	Yemen	2008	250	Prevalence of T2DM: 10.4%	FPG and OGTT
Abdul-Rahim <i>et al</i> ^[23]	Palestine	2001	302	Prevalence of T2DM: 12%	OGTT
Ajlouni <i>et al</i> ^[64]	Jordan	2008	1121	Prevalence of T2DM: 17.4%	FPG
Albache <i>et al</i> ^[65]	Syria	2010	806	Prevalence of T2DM: 15.6%	FPG
Hirbli <i>et al</i> ^[66]	Lebanon	2005	3000	Prevalence of T2DM: 15.6%	FPG
Herman <i>et al</i> ^[67]	Egypt	1998	1451	Prevalence of T2DM: 9.3%	OGTT
Abolfotouh <i>et al</i> ^[68]	Egypt	2008	1800	Prevalence of T2DM: 3.7%	FBG
Elbagir <i>et al</i> ^[25]	Sudan	1996	1284	Prevalence of T2DM: 3.4%	OGTT
Noor <i>et al</i> ^[69]	Sudan	2015	1111	Prevalence of T2DM: 1.3% Prevalence of undiagnosed T2DM: 2.6%	FBG
Bouguerra <i>et al</i> ^[26]	Tunisia	2007	3729	Prevalence of T2DM: 9.9%	FPG
Ben Romdhane <i>et al</i> ^[70]	Tunisia	2014	7700	Prevalence of T2DM: 15.1%	FPG
Kadiki <i>et al</i> ^[71]	Libya	2001	868	Prevalence of T2DM: 14.1%	OGTT
Rguibi <i>et al</i> ^[72]	Morocco	2006	249	Prevalence of undiagnosed T2DM: 6.4%	FPG
Bos <i>et al</i> ^[29]	North Africa	2013	NA	Prevalence of diabetes: Range from 2.6% in rural Sudan to 20.0% in urban Egypt Prevalence of diabetes significantly higher in urban than rural areas Significantly higher prevalence of overweight/obesity in females than males in Algeria, Egypt, Morocco, Tunisia and Sudan	NA
Jaber <i>et al</i> ^[73]	United States (Arab-Americans)	2003	542	Prevalence of T2DM in males: 22.0% Prevalence T2DM in females: 18.0%	OGTT
Rissel <i>et al</i> ^[74]	Australia (Arab immigrants)	1998	528	Prevalence of overweight or obesity in males: 73% Prevalence of overweight or obesity in females: 36%	NA
Thow <i>et al</i> ^[75]	Australia (people born in Middle East and North Africa)	2005	NA	Highest prevalence and incidence of T2DM Second highest ratio of hospitalization and mortality Standard prevalence ratio for diabetes among Arabic-speaking subjects significantly 3.6 times higher than English-only speaking subjects	NA

WHO: World Health Organization; OGTT: Oral glucose tolerance test; FBG: Fasting blood glucose; FPG: Fasting plasma glucose; UAE: United Arab Emirates; NA: Data not available; T2DM: Type-2 diabetes mellitus.

Table 2 Prevalence of type-2 diabetes mellitus in Arab podiatric and children

Ref.	Country	Year	Sample size	Main findings	Diagnostic technique	Notes
Punnose <i>et al</i> ^[76]	UAE	2005	96	11 children diagnosed with T2DM 9/11 children were Arab origin 8/11 children were overweight or obese 10/11 children were female	FPG	(8-18 years old) Case series
Moussa <i>et al</i> ^[6]	Kuwait	2008	128918	T2DM found in 45 children Prevalence of T2DM in male children: 47.3/10000 Prevalence of T2DM in female children: 26.3/10000 ($P = 0.05$)	NA	(6-18 years old) Medical record review
Al-Agha <i>et al</i> ^[77]	Saudi Arabia	2012	387	Prevalence of T2DM: 9.04%	NA	(2-18 years old) Retrospective cross-sectional study
Al-Rubeaan <i>et al</i> ^[7]	Saudi Arabia	2015	23523	Age adjusted Prevalence of T2DM: 1/1000	FPG	≤ 18 yr
Ali <i>et al</i> ^[78]	Egypt	2013	210	28 out of 210 children with diabetes diagnosed with T2DM 64.3% of T2DM children were female ($P = 0.04$)	Fasting serum C-peptide levels	(1-18 years old)
Osman <i>et al</i> ^[79]	Sudan	2013	958	38/985 children identified with T2DM 32/38 of cases were from tribes of Arab origin	NA	(11-18 years old) Retrospective cross sectional
Ehtisham <i>et al</i> ^[80]	United Kingdom	2000	8	First 8 cases reported with T2DM in United Kingdom All cases were overweight and originated from India, Pakistan and Arab countries	NA	(9-16 years old) Retrospective cross sectional

UAE: United Arab Emirates; FPG: Fasting plasma glucose; NA: Data not available; T2DM: Type-2 diabetes mellitus.

improved medical services, access to education and other “modern” conveniences. There are significant differences in the rate of T2DM between rural and urban communities. For example, an early study in Saudi Arabia found that the prevalence of T2DM in urban communities was 12% and 14% in males and females respectively, which was nearly double the prevalence of T2DM in males and females residing rural areas (7% and 7.7% for males and females respectively)^[28]. Another study in Oman indicated that urban residence was significantly associated with T2DM (OR = 1.7, 95%CI: 1.4-2.1), with the prevalence of T2DM was 17.7% and 10.5 in urban and rural areas respectively^[21]. Moreover, a systematic review of the prevalence of T2DM in North Africa found that the prevalence of T2DM ranged from 2.6% in rural Sudan to 20.0% in urban Egypt^[29].

Dietary habits

The Mediterranean diet is considered to be one of the healthiest food options available, as it contains a variety of fruits, vegetables, grains and olive oil. In fact, several studies have shown significant reduction in the rate of T2DM with the Mediterranean diet^[30,31]. However, one is unlikely to obtain the health benefits of the Mediterranean diet without proper adherence, which may be a common habit in most of the Eastern Mediterranean countries. In a comparative risk assessment analysis, data from the United Food and Agricultural Organization was used to estimate the dietary intake of 20 countries in the Middle East and North Africa^[32]. These estimates were used to provide a country specific estimates of cardio-metabolic disease mortality secondary to 15 different dietary and metabolic risk factors. This analysis shows that there is suboptimal intake of the “protective” diets (*e.g.*, fruits, vegetables

and sea food), and greater consumption of “harmful” diets (*e.g.*, processed meat and trans fatty acids). These results were reflected in the cardio-metabolic disease mortality rate, where non-optimal BMI was the second leading metabolic risk factor for cardio-metabolic disease mortality, accounting for 21% of all cardio-metabolic mortality risk factors, followed by high fasting blood glucose (> 5.3 mmol/L) which accounted for 17% of all cardio-metabolic disease deaths.

Sedentary life style

Numerous studies confirm that physical activity reduces the incidence and/or severity of T2DM^[33-35]. Six years of leading an active life coupled with a healthy diet can reduce the incidence of T2DM by 43% in subjects with impaired glucose tolerance followed for 20 years^[36]. Another meta-analysis shows that exercise training reduces glycosylated haemoglobin (HbA1c) by 0.66% in type-2 diabetic patients, a percentage that should substantially reduce the complications of T2DM^[37]. Not surprisingly, a sedentary life style is one of the most important modifiable risk factors in the Arab world, specifically when comparing the prevalence of highly active subjects in the Arab world with the global data. Among 52746 subject from 20 countries included to study the prevalence of physical activity, 8 countries reported that more than 50% of the population are highly active based on the international physical activity questionnaire^[38]. Saudi Arabia, which was the only country from the Arab world that was included in their analysis, is reported to have 26.2% of their population as being highly active. More recent data came from a study over 10 Eastern Mediterranean countries indicating that the highest level of physically active adolescents were in the Emirates (23.9%), while the lowest was in Egypt

Table 3 Diabetes complications in the Arab world

Country	Year	Sample size	Prevalence of complication	Ref.
Saudi Arabia	2015	50464	Retinopathy: 19.7%	[81]
	2015	3800	Blindness: 33%	[82]
	2014	54670	Nephropathy: 10.8%	[83]
	2015	62681	Diabetic foot: 3.3%	[84]
			Foot ulcer: 2.05%	
			Gangrene: 0.19%	
			Amputation: 1.06%	
	2014	552	Peripheral neuropathy: 19.9%	[85]
Kuwait	2007	165	Retinopathy: 40%	[86]
Emirates	2007	513	Retinopathy: 19%	[87]
	2007	2455	Retinopathy: 54.2%	[57]
			Nephropathy: 40.8%	
			Neuropathy: 34.7%	
			Peripheral vascular disease: 11.1%	
Bahrain	2009	712	Microalbuminuria: 27.9%	[88]
	2007	1477	Neuropathy: 36.6%	[89]
			Foot ulcer: 5.9%	
			Peripheral vascular disease: 11.8%	
Qatar	2011	540	Retinopathy: 23.5%	[90]
	2014	1633	Retinopathy: 12.5%	[91]
			Nephropathy: 12.4%	
			Neuropathy: 9.5%	
Oman	2003	2249	Retinopathy: 14.9%	[92]
	2009	418	Retinopathy: 7.9%	[93]
	2012	2551	Microalbuminuria: 37%	[94]
			Nephropathy: 5%	
	2012	699	Nephropathy: 42.5%	[95]
Yemen	2011	694	Blindness: 15.7%	[96]
	2009	350	Retinopathy: 55%	[97]
	1997	1095	Peripheral neuropathy: 40.7%	[98]
	2010	311	Peripheral vascular disease: 9.1%	[99]
Jordan	2015	3638	Blindness: 1.3%	[100]
			Severe visual impairment: 1.82%	
			Correctable visual impairment: 9.49%	
	2008	986	Retinopathy: 64.1%	[101]
	2005	986	Blindness: 7.4%	[102]
	2003	1142	Microalbuminuria: 33%	[103]
			Ulceration: 4%	
			Amputation: 5%	
Egypt	2011	1325	Retinopathy: 20.5%	[104]
	2015	2000	Neuropathy: 29.3%	[105]
			Peripheral vascular disease: 11%	
	1998	4600	Retinopathy: 42%	[67]
			Blindness: 5%	
			Nephropathy: 7%	
			Neuropathy: 22%	
			Foot ulcer: 1%	
Tunisia	2014	2320	Retinopathy: 26.3%	[106]
Libya	2012	260	Retinopathy: 16.2%	[107]
			Nephropathy: 1.5%	
			Neuropathy: 11.2%	

(9.2%), giving an overall prevalence of physically active adolescents in the Eastern Mediterranean countries of 19%^[39].

Other factors

Several factors can explain the unrestrained raise in the rate of T2DM in the Arabian area. Some are attributed to the Eastern cultural heritage from a hundred of years ago, such as multiple pregnancies and cultural barriers

for women's physical activity. However, despite no changes in the traditional risk factors for T2DM in Arabian area, there is an alarming increase in the prevalence of diabetes, particularly within the last two decades - suggesting that recent lifestyle changes may have greater effect on this crisis. The global change impacts the Arab nations even more dramatically than elsewhere: Temperatures that are already scorching on a regular basis are now increased (higher temperatures for longer periods), even more increases in polluted and dusty air. These conditions combine to further discourage many people - regardless of age or gender - from any kind of outdoor activity. The situation is made even worse by the political instability in many of these countries, which affects access to healthy food and medical care.

COMPLICATIONS

According to the World Health Organization, diabetes is the 8th leading cause of death in the world^[40]. Data published specifically from the Arab world shows a similar trend to that available globally. A recent analysis indicates that diabetes represents the 5th leading cause of death in the Arab world in 2010, compared to it being the 11th leading cause of death in 1990^[41]. Living with T2DM is troublesome as well, as diabetes is the 5th leading cause for the disability-adjusted life years in high income Arabic countries in 2010, compared to it being ranked as the 10th reason in twenty years earlier^[41]. The studies summarized in Table 3 summarize the most recent data on the prevalence of common complications (retinopathy, nephropathy, neuropathy and peripheral vascular diseases) in diabetic patients from the Arab world.

FUTURE DIRECTIONS

The high prevalence of T2DM in Arab nations offers an opportunity to better understand the disease and its treatment. Unfortunately, current research in the Arab nations does not match the level of this health crisis in the area. Large portions of critical data information are unavailable in many countries from the Arab world. For instance, predicting the prevalence of T2DM statistically could be crucial in formulating a strategic plan for combating the disease, which requires comprehensive knowledge about its current burden, for which data is available only from Tunisia and Saudi Arabia. The Tunisian study revealed that the prevalence of T2DM in Tunisia will reach 26.6% in 2027^[42]. Moreover, it predicts that a 20% reduction in obesity and smoking will yield in a 3.3% reduction in T2DM by 2027. On the other hand, the Saudi study indicates that the prevalence of T2DM in Saudi Arabia could reach 44.1% in 2022, a figure which differs significantly from IDF estimates^[43].

It would be important to apply the recommendations on physical activity discussed at conference on Healthy Lifestyles and Non-Communicable Diseases in the Arab World and the Middle East, also called the "Riyadh

declaration^[44]. To successfully implement the recommendations of the Riyadh declaration, novel research is needed to determine the social determinants for developing diabetes in the Arab world. For instance, a population based longitudinal cohort of 5124 diabetes-free participants in United States revealed that people residing neighborhoods with fewer opportunities for physical activity have nearly double the risk of developing T2DM^[45].

Considering the epidemic nature of obesity and T2DM in the Arab world, studies on the ethnic-specific obesity cut-off points for the risk of diabetes are certainly necessary for peoples of the Arab and North African populations. For example, the risk of diabetes increases with BMI values greater than 25 kg/m² for South Asians, at 27 kg/m² for African-Caribbeans and at 30 kg/m² for Europeans^[46].

CONCLUSION

The data obtained from the Arabic world indicates that there is an uncontrolled rise in the prevalence of T2DM over the last two decades, in particular within the Gulf cooperation countries. For example, the prevalence of T2DM in early 1980's was estimated 2.4%^[8], and then increased to 12% in the late 1990's^[28], while recent data from Saudi Arabia shows that the prevalence of T2DM reached 25.4% in 2014. Given that obesity is a major risk factor for developing T2DM, obesity is associated with T2DM in Arab countries even where the prevalence of T2DM is relatively low. In addition, other factors such as rapid urbanization, unhealthy dietary habits and the lack of physical activity are key determinants of T2DM in the area. With this uncontrolled rise in the rate of T2DM in the Arab world, T2DM has now become the 5th leading cause of death in the Arab world. To better estimate the size of this crisis, studies aimed at predicting the rate of T2DM in the future are urgently needed. However, the vast majority of Arabian countries do not provide this important information. In order to successfully contain the uncontrolled rise of T2DM in the Arabian region, one should take advantage of the research conducted in other communities facing similar patterns in the increasing rates of diabetes. For example, genetic studies, ethnic-specific obesity cut-off points for the risk of diabetes studies and community studies to assess the appropriateness of the neighborhoods for physical activity may bring about increased awareness on the epidemic of diabetes sweeping the region-and so help in creating national/regional strategies to successfully limit the widespread firestorm of T2DM ravaging the Arabic region.

REFERENCES

- 1 **International Diabetes Federation.** IDF Diabetes Atlas, 6th edition. Brussels, Belgium: International Diabetes Federation, 2013. Available from: URL: <http://www.idf.org/diabetesatlas>
- 2 **American Diabetes Association.** Economic costs of diabetes in the U.S. In 2007. *Diabetes Care* 2008; **31**: 596-615 [PMID: 18308683 DOI: 10.2337/dc08-9017]

- 3 **World Health Organization.** The World Health Statistics. 2008. Available from: URL: <http://www.who.int/whosis/whostat/2008/en/index.ht>
- 4 **Al-Maskari F,** El-Sadig M, Nagelkerke N. Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates. *BMC Public Health* 2010; **10**: 679 [PMID: 21059202 DOI: 10.1186/1471-2458-10-679]
- 5 **Badran M,** Laher I. Type II Diabetes Mellitus in Arabic-Speaking Countries. *Int J Endocrinol* 2012; **2012**: 902873 [PMID: 22851968 DOI: 10.1155/2012/902873]
- 6 **Moussa MA,** Alsaied M, Abdella N, Refai TM, Al-Sheikh N, Gomez JE. Prevalence of type 2 diabetes mellitus among Kuwaiti children and adolescents. *Med Princ Pract* 2008; **17**: 270-275 [PMID: 18523392 DOI: 10.1159/000129604]
- 7 **Al-Rubeaan K.** National surveillance for type 1, type 2 diabetes and prediabetes among children and adolescents: a population-based study (SAUDI-DM). *J Epidemiol Community Health* 2015; **69**: 1045-1051 [PMID: 26085648 DOI: 10.1136/jech-2015-205710]
- 8 **Bacchus RA,** Bell JL, Madkour M, Kilshaw B. The prevalence of diabetes mellitus in male Saudi Arabs. *Diabetologia* 1982; **23**: 330-332 [PMID: 7141167 DOI: 10.1007/BF00253739]
- 9 **Fatani HH,** Mira SA, el-Zubier AG. Prevalence of diabetes mellitus in rural Saudi Arabia. *Diabetes Care* 1987; **10**: 180-183 [PMID: 3582078 DOI: 10.2337/diacare.10.2.180]
- 10 **Al-Rubeaan K,** Al-Manaa HA, Khoja TA, Ahmad NA, Al-Sharqawi AH, Siddiqui K, Alnaqeb D, Aburishheh KH, Youssef AM, Al-Batel A, Alotaibi MS, Al-Gamdi AA. Epidemiology of abnormal glucose metabolism in a country facing its epidemic: SAUDI-DM study. *J Diabetes* 2015; **7**: 622-632 [PMID: 25266306 DOI: 10.1111/1753-0407]
- 11 **Dabelea D,** Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton JW, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. *JAMA* 2014; **311**: 1778-1786 [PMID: 24794371 DOI: 10.1001/jama.2014.3201]
- 12 **Zeitler P,** Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, Maahs D. ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. *Pediatr Diabetes* 2014; **15** Suppl 20: 26-46 [PMID: 25182306 DOI: 10.1111/pedi.12179]
- 13 **Abuyassin B,** Laher I. Obesity-linked diabetes in the Arab world: a review. *East Mediterr Health J* 2015; **21**: 420-439 [PMID: 26370001]
- 14 **Signal RJ,** Kenny GP, Wasserman DH, Castaneda-Sceppa C. Physical activity/exercise and type 2 diabetes. *Diabetes Care* 2004; **27**: 2518-2539 [PMID: 15451933 DOI: 10.2337/diacare.27.10.2518]
- 15 **Bonora E,** Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. *Diabet Med* 2004; **21**: 52-58 [PMID: 14706054 DOI: 10.1046/j.1464-5491.2003.01068.x]
- 16 **Masuo K,** Rakugi H, Ogiwara T, Esler MD, Lambert GW. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. *Curr Diabetes Rev* 2010; **6**: 58-67 [PMID: 20034369 DOI: 10.2174/157339910790909396]
- 17 **Tobias DK,** Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, Manson JE, Hu FB. Body-mass index and mortality among adults with incident type 2 diabetes. *N Engl J Med* 2014; **370**: 233-244 [PMID: 24428469 DOI: 10.1056/NEJMoa1304501]
- 18 **Logue J,** Walker JJ, Leese G, Lindsay R, McKnight J, Morris A, Philip S, Wild S, Sattar N. Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. *Diabetes Care* 2013; **36**: 887-893 [PMID: 23139375 DOI: 10.2337/dc12-0944]
- 19 **Al-Shahrani A,** Al-Khaldi Y. Obesity among diabetic and

- hypertensive patients in Aseer region, Saudi Arabia. *Saudi J Obes* 2013; **1**: 14-17 [DOI: 10.4103/2347-2618.119470]
- 20 **Alarouj M**, Bennakhi A, Alnesef Y, Sharifi M, Elcum N. Diabetes and associated cardiovascular risk factors in the State of Kuwait: the first national survey. *Int J Clin Pract* 2013; **67**: 89-96 [PMID: 23241053 DOI: 10.1111/ijcp.12064]
- 21 **Al-Moosa S**, Allin S, Jemai N, Al-Lawati J, Mossialos E. Diabetes and urbanization in the Omani population: an analysis of national survey data. *Popul Health Metr* 2006; **4**: 5 [PMID: 16635266 DOI: 10.1186/1478-7954-4-5]
- 22 **Bener A**, Zirie M, Janahi IM, Al-Hamaq AO, Musallam M, Wareham NJ. Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar. *Diabetes Res Clin Pract* 2009; **84**: 99-106 [PMID: 19261345 DOI: 10.1016/j.diabres.2009.02.003]
- 23 **Abdul-Rahim HF**, Husseini A, Giacaman R, Jervell J, Bjertness E. Diabetes mellitus in an urban Palestinian population: prevalence and associated factors. *East Mediterr Health J* 2001; **7**: 67-78 [PMID: 12596954]
- 24 **Naja F**, Hwalla N, Itani L, Salem M, Azar ST, Zeidan MN, Nasreddine L. Dietary patterns and odds of Type 2 diabetes in Beirut, Lebanon: a case-control study. *Nutr Metab (Lond)* 2012; **9**: 111 [PMID: 23270372 DOI: 10.1186/1743-7075-9-111]
- 25 **Elbagir MN**, Eltom MA, Elmahadi EM, Kadam IM, Berne C. A population-based study of the prevalence of diabetes and impaired glucose tolerance in adults in northern Sudan. *Diabetes Care* 1996; **19**: 1126-1128 [PMID: 8886561 DOI: 10.2337/diacare.19.10.1126]
- 26 **Bouguerra R**, Alberti H, Salem LB, Rayana CB, Atti JE, Gaigi S, Slama CB, Zouari B, Alberti K. The global diabetes pandemic: the Tunisian experience. *Eur J Clin Nutr* 2007; **61**: 160-165 [PMID: 16900086 DOI: 10.1038/sj.ejcn.1602478]
- 27 **Kahan D**. Prevalence and correlates of adult overweight in the Muslim world: analysis of 46 countries. *Clin Obes* 2015; **5**: 87-98 [PMID: 25755091 DOI: 10.1111/cob.12089]
- 28 **Al-Nuaim AR**. Prevalence of glucose intolerance in urban and rural communities in Saudi Arabia. *Diabet Med* 1997; **14**: 595-602 [PMID: 9223399 DOI: 10.1002/(SICI)1096-9136(199707)14:7<595::AID-DIA377>3.0.CO;2-C]
- 29 **Bos M**, Agyemang C. Prevalence and complications of diabetes mellitus in Northern Africa, a systematic review. *BMC Public Health* 2013; **13**: 387 [PMID: 23617762 DOI: 10.1186/1471-2458-13-387]
- 30 **Martínez-González MA**, de la Fuente-Arrillaga C, Nunez-Cordoba JM, Basterra-Gortari FJ, Beunza JJ, Vazquez Z, Benito S, Tortosa A, Bes-Rastrollo M. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. *BMJ* 2008; **336**: 1348-1351 [PMID: 18511765 DOI: 10.1136/bmj.39561.501007.BE]
- 31 **Salas-Salvadó J**, Bulló M, Babio N, Martínez-González MÁ, Ibarrola-Jurado N, Basora J, Estruch R, Covas MI, Corella D, Arós F, Ruiz-Gutiérrez V, Ros E. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care* 2011; **34**: 14-19 [PMID: 20929998 DOI: 10.2337/dc10-1288]
- 32 **Afshin A**, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, Singh G, Yakoob MY, Abdollahi M, Al-Hooti S, Farzadfar F, Houshiar-Rad A, Hwalla N, Koksai E, Musaiger A, Pekcan G, Sibai AM, Zaghoul S, Danaei G, Ezzati M, Mozaffarian D. The impact of dietary habits and metabolic risk factors on cardiovascular and diabetes mortality in countries of the Middle East and North Africa in 2010: a comparative risk assessment analysis. *BMJ Open* 2015; **5**: e006385 [PMID: 25995236 DOI: 10.1136/bmjopen-2014-006385]
- 33 **Sigal RJ**, Armstrong MJ, Colby P, Kenny GP, Plotnikoff RC, Reichert SM, Riddell MC. Physical activity and diabetes. *Can J Diabetes* 2013; **37** Suppl 1: S40-S44 [PMID: 24070962 DOI: 10.1016/j.cjcd.2013.01.018]
- 34 **LaMonte MJ**, Blair SN, Church TS. Physical activity and diabetes prevention. *J Appl Physiol* (1985) 2005; **99**: 1205-1213 [PMID: 16103523]
- 35 **Sigal RJ**, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. *Diabetes Care* 2006; **29**: 1433-1438 [PMID: 16732040 DOI: 10.2337/dc06-9910]
- 36 **Li G**, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. *Lancet* 2008; **371**: 1783-1789 [PMID: 18502303 DOI: 10.1016/S0140-6736(08)6076-6]
- 37 **Boulé NG**, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. *JAMA* 2001; **286**: 1218-1227 [PMID: 11559268]
- 38 **Bauman A**, Bull F, Chey T, Craig CL, Ainsworth BE, Sallis JF, Bowles HR, Hagstromer M, Sjostrom M, Pratt M. The International Prevalence Study on Physical Activity: results from 20 countries. *Int J Behav Nutr Phys Act* 2009; **6**: 21 [PMID: 19335883 DOI: 10.1186/1479-5868-6-21]
- 39 **Al Subhi LK**, Bose S, Al Ani MF. Prevalence of physically active and sedentary adolescents in 10 Eastern Mediterranean countries and its relation with age, sex, and body mass index. *J Phys Act Health* 2015; **12**: 257-265 [PMID: 24763105 DOI: 10.1123/jpah.2013-0134]
- 40 **World Health Organization**. Fact sheet No. 310. 2014. Available from: URL: <http://www.who.int/mediacentre/factsheets/fs310/en>
- 41 **Mokdad AH**, Jaber S, Aziz MI, AlBuhairan F, AlGhaithi A, AlHamad NM, Al-Hooti SN, Al-Jasari A, AlMazroa MA, AlQasbi AM, Alswaidi S, Asad M, Atkinson C, Badawi A, Bakfalouni T, Barkia A, Biryukov S, El Bcheraoui C, Daoud F, Forouzanfar MH, Gonzalez-Medina D, Hamadeh RH, Hsairi M, Hussein SS, Karam N, Khalifa SE, Khoja TA, Lami F, Leach-Kemon K, Memish ZA, Mokdad AA, Naghavi M, Nasher J, Qasem MB, Shuaib M, Al Thani AA, Al Thani MH, Zamakhshary M, Lopez AD, Murray CJ. The state of health in the Arab world, 1990-2010: an analysis of the burden of diseases, injuries, and risk factors. *Lancet* 2014; **383**: 309-320 [PMID: 24452042 DOI: 10.1016/S0140-6736(13)62189-3]
- 42 **Saidi O**, O'Flaherty M, Mansour NB, Aissi W, Lassoued O, Capewell S, Critchley JA, Malouche D, Romdhane HB. Forecasting Tunisian type 2 diabetes prevalence to 2027: validation of a simple model. *BMC Public Health* 2015; **15**: 104 [PMID: 25885910 DOI: 10.1186/s12889-015-1416-z]
- 43 **Al-Quwaidhi AJ**, Pearce MS, Sobngwi E, Critchley JA, O'Flaherty M. Comparison of type 2 diabetes prevalence estimates in Saudi Arabia from a validated Markov model against the International Diabetes Federation and other modelling studies. *Diabetes Res Clin Pract* 2014; **103**: 496-503 [PMID: 24447810 DOI: 10.1016/j.diabres.2013.12.036]
- 44 **Bull F**, Dvorak J. Tackling chronic disease through increased physical activity in the Arab World and the Middle East: challenge and opportunity. *Br J Sports Med* 2013; **47**: 600-602 [PMID: 23624465 DOI: 10.1136/bjsports-2012-092109]
- 45 **Christine PJ**, Auchincloss AH, Bertoni AG, Carnethon MR, Sánchez BN, Moore K, Adar SD, Horwich TB, Watson KE, Diez Roux AV. Longitudinal Associations Between Neighborhood Physical and Social Environments and Incident Type 2 Diabetes Mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA). *JAMA Intern Med* 2015; **175**: 1311-1320 [PMID: 26121402 DOI: 10.1001/jamainternmed.2015.2691]
- 46 **Tillin T**, Sattar N, Godsland IF, Hughes AD, Chaturvedi N, Forouhi NG. Ethnicity-specific obesity cut-points in the development of Type 2 diabetes - a prospective study including three ethnic groups in the United Kingdom. *Diabet Med* 2015; **32**: 226-234 [PMID: 25186015 DOI: 10.1111/dme.12576]
- 47 **Rahman Al-Nuaim A**. Effect of overweight and obesity on glucose intolerance and dyslipidemia in Saudi Arabia, epidemiological study. *Diabetes Res Clin Pract* 1997; **36**: 181-191 [PMID: 9237785 DOI: 10.1016/S0168-8227(97)00041-7]
- 48 **el-Hazmi MA**, Wasy AS. Prevalence of overweight and obesity in diabetic and non-diabetic Saudis. *East Mediterr Health J* 2000; **6**:

- 276-282 [PMID: 11556013]
- 49 **Al-Nozha MM**, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. Diabetes mellitus in Saudi Arabia. *Saudi Med J* 2004; **25**: 1603-1610 [PMID: 15573186]
- 50 **Almajwal AM**, Al-Baghli NA, Batterham MJ, Williams PG, Al-Turki KA, Al-Ghamdi AJ. Performance of body mass index in predicting diabetes and hypertension in the Eastern Province of Saudi Arabia. *Ann Saudi Med* 2009; **29**: 437-445 [PMID: 19847080 DOI: 10.4103/0256-4947.57165]
- 51 **Al-Rubeaan K**, Al-Manaa H, Khoja T, Ahmad N, Al-Sharqawi A, Siddiqui K, AlNaqeb D, Aburishheh K, Youssef A, Al-Batil A, Al-Otaibi M, Ghamdi AA. The Saudi Abnormal Glucose Metabolism and Diabetes Impact Study (SAUDI-DM). *Ann Saudi Med* 2014; **34**: 465-475 [PMID: 25971818 DOI: 10.5144/0256-4947.2014.465]
- 52 **El Bcheraoui C**, Basulaiman M, Tuffaha M, Daoud F, Robinson M, Jaber S, Mikhitarian S, Memish ZA, Al Saeedi M, AlMazroa MA, Mokdad AH. Status of the diabetes epidemic in the Kingdom of Saudi Arabia, 2013. *Int J Public Health* 2014; **59**: 1011-1021 [PMID: 25292457 DOI: 10.1007/s00038-014-0612-4]
- 53 **Abdella N**, Khogali M, al-Ali S, Gumaa K, Bajaj J. Known type 2 diabetes mellitus among the Kuwaiti population. A prevalence study. *Acta Diabetol* 1996; **33**: 145-149 [PMID: 8870817 DOI: 10.1007/BF00569425]
- 54 **Al Khalaf MM**, Eid MM, Najjar HA, Alhajry KM, Doi SA, Thalib L. Screening for diabetes in Kuwait and evaluation of risk scores. *East Mediterr Health J* 2010; **16**: 725-731 [PMID: 20799528]
- 55 **Al Zurba FI**, Al Garf A. Prevalence of diabetes mellitus among Bahrainis attending primary health care centres. *East Mediterr Health J* 1996; **2**: 274-282
- 56 **Malik M**, Bakir A, Saab BA, King H. Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. *Diabetes Res Clin Pract* 2005; **69**: 188-195 [PMID: 16005369 DOI: 10.1016/j.diabres.2004.12.005]
- 57 **Saadi H**, Carruthers SG, Nagelkerke N, Al-Maskari F, Afandi B, Reed R, Lukic M, Nicholls MG, Kazam E, Algawi K, Al-Kaabi J, Leduc C, Sabri S, El-Sadig M, Elkhumaidi S, Agarwal M, Benedict S. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. *Diabetes Res Clin Pract* 2007; **78**: 369-377 [PMID: 17532085 DOI: 10.1016/j.diabres.2007.04.008]
- 58 **Mansour AA**, Al-Jazairi MI. Predictors of incident diabetes mellitus in Basrah, Iraq. *Ann Nutr Metab* 2007; **51**: 277-280 [PMID: 17622787 DOI: 10.1159/000105449]
- 59 **Mansour AA**, Al-Maliki AA, Kasem B, Jabar A, Mosbeh KA. Prevalence of diagnosed and undiagnosed diabetes mellitus in adults aged 19 years and older in Basrah, Iraq. *Diabetes Metab Syndr Obes* 2014; **7**: 139-144 [PMID: 24833912 DOI: 10.2147/DMSO.S59652]
- 60 **Al-Lawati JA**, Panduranga P, Al-Shaikh HA, Morsi M, Mohsin N, Khandekar RB, Al-Lawati HJ, Bayoumi RA. Epidemiology of Diabetes Mellitus in Oman: Results from two decades of research. *Sultan Qaboos Univ Med J* 2015; **15**: e226-e233 [PMID: 26052456]
- 61 **Musaiger A**, Shahbeek N. The relationship between obesity and prevalence of chronic diseases in the Arab women. *J Hum Ecol Special Issue* 2005; **13**: 97-100
- 62 **Al-Habori M**, Al-Mamari M, Al-Meer A. Type II Diabetes Mellitus and impaired glucose tolerance in Yemen: prevalence, associated metabolic changes and risk factors. *Diabetes Res Clin Pract* 2004; **65**: 275-281 [PMID: 15331208 DOI: 10.1016/j.diabres.2004.02.001]
- 63 **Gunaid AA**, Assabri AM. Prevalence of type 2 diabetes and other cardiovascular risk factors in a semirural area in Yemen. *East Mediterr Health J* 2008; **14**: 42-56 [PMID: 18557451]
- 64 **Ajlouni K**, Khader YS, Batieha A, Ajlouni H, El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. *J Diabetes Complications* 2008; **22**: 317-324 [PMID: 18413210 DOI: 10.1016/j.jdiacomp.2007.01.004]
- 65 **Albache N**, Al Ali R, Rastam S, Fouad FM, Mzayek F, Maziak W. Epidemiology of Type 2 diabetes mellitus in Aleppo, Syria. *J Diabetes* 2010; **2**: 85-91 [PMID: 20923489 DOI: 10.1111/j.1753-0407.2009.00063]
- 66 **Hirbli KI**, Jambeine MA, Slim HB, Barakat WM, Habis RJ, Francis ZM. Prevalence of diabetes in greater Beirut. *Diabetes Care* 2005; **28**: 1262 [PMID: 15855610 DOI: 10.2337/diacare.28.5.1262]
- 67 **Herman WH**, Aubert RE, Engelgau MM, Thompson TJ, Ali MA, Sous ES, Hegazy M, Badran A, Kenny SJ, Gunter EW, Malarcher AM, Brechner RJ, Wetterhall SF, DeStefano F, Smith PJ, Habib M, abd el Shakour S, Ibrahim AS, el Behairy EM. Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. *Diabet Med* 1998; **15**: 1045-1051 [PMID: 9868980 DOI: 10.1002/(SICI)1096-9136(1998120)15:12<1045::AID-DIA696>3.0.CO;2-L]
- 68 **Abolfotouh MA**, Soliman LA, Mansour E, Farghaly M, El-Dawaiaty AA. Central obesity among adults in Egypt: prevalence and associated morbidity. *East Mediterr Health J* 2008; **14**: 57-68 [PMID: 18557452]
- 69 **Noor SK**, Bushara SO, Sulaiman AA, Elmadhoun WM, Ahmed MH. Undiagnosed diabetes mellitus in rural communities in Sudan: prevalence and risk factors. *East Mediterr Health J* 2015; **21**: 164-170 [PMID: 26074216]
- 70 **Ben Romdhane H**, Ben Ali S, Aissi W, Traissac P, Aounallah-Skhiri H, Bougateg S, Maire B, Delpuech F, Achour N. Prevalence of diabetes in Northern African countries: the case of Tunisia. *BMC Public Health* 2014; **14**: 86 [PMID: 24472619 DOI: 10.1186/1471-2458-14-86]
- 71 **Kadiki OA**, Roaeid RB. Prevalence of diabetes mellitus and impaired glucose tolerance in Benghazi Libya. *Diabetes Metab* 2001; **27**: 647-654 [PMID: 11852372]
- 72 **Rguibi M**, Belahsen R. Prevalence and associated risk factors of undiagnosed diabetes among adult Moroccan Sahraoui women. *Public Health Nutr* 2006; **9**: 722-727 [PMID: 16925877 DOI: 10.1079/PHN2005866]
- 73 **Jaber LA**, Brown MB, Hammad A, Nowak SN, Zhu Q, Ghafoor A, Herman WH. Epidemiology of diabetes among Arab Americans. *Diabetes Care* 2003; **26**: 308-313 [PMID: 12547854]
- 74 **Rissel C**, Lesjak M, Ward J. Cardiovascular risk factors among Arabic-speaking patients attending Arabic-speaking general practitioners in Sydney, Australia: opportunities for intervention. *Ethn Health* 1998; **3**: 213-222 [PMID: 9798119 DOI: 10.1080/1357858.1998.9961863]
- 75 **Thow AM**, Waters AM. AIHW 2005. Diabetes in culturally and linguistically diverse Australians. Cat. No. CVD 30. Canberra: Australian Institute of Health and Welfare, 2005
- 76 **Punnose J**, Agarwal MM, Bin-Uthman S. Type 2 diabetes mellitus among children and adolescents in Al-Ain: a case series. *East Mediterr Health J* 2005; **11**: 788-797 [PMID: 16700395]
- 77 **Al-Agha A**, Ocheltree A, Shata N. Prevalence of hyperinsulinism, type 2 diabetes mellitus and metabolic syndrome among Saudi overweight and obese pediatric patients. *Minerva Pediatr* 2012; **64**: 623-631 [PMID: 23108324]
- 78 **Ali BA**, Abdallah ST, Abdallah AM, Hussein MM. The Frequency of Type 2 Diabetes Mellitus among Diabetic Children in El Minia Governorate, Egypt. *Sultan Qaboos Univ Med J* 2013; **13**: 399-403 [PMID: 23984025 DOI: 10.12816/0003262]
- 79 **Osman H**, Elsadek N, Abdullah M. Type 2 diabetes in Sudanese children and adolescents. *Sudan J Paediatr* 2013; **13**: 17-23
- 80 **Ehtisham S**, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children--an emerging problem. *Diabet Med* 2000; **17**: 867-871 [PMID: 11168330 DOI: 10.1046/j.1464-5491.2000.00409.x]
- 81 **Al-Rubeaan K**, Abu El-Asrar AM, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, Alguwaihes A, Alotaibi MS, Al-Ghamdi A, Ibrahim HM. Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. *Acta Ophthalmol* 2015; **93**: e140-e147 [PMID: 25270515 DOI: 10.1111/aos.12532]
- 82 **Hajar S**, Al Hazmi A, Wasli M, Mousa A, Rabiou M. Prevalence

- and causes of blindness and diabetic retinopathy in Southern Saudi Arabia. *Saudi Med J* 2015; **36**: 449-455 [PMID: 25828282 DOI: 10.15537/smj.2015.4.10371]
- 83 **Al-Rubeaan K**, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, Al-Mutlaq HM, David SK, AlNaqeb D. Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. *PLoS One* 2014; **9**: e88956 [PMID: 24586457 DOI: 10.1371/journal.pone.0088956]
 - 84 **Al-Rubeaan K**, Al Derwish M, Ouizi S, Youssef AM, Subhani SN, Ibrahim HM, Alamri BN. Diabetic foot complications and their risk factors from a large retrospective cohort study. *PLoS One* 2015; **10**: e0124446 [PMID: 25946144 DOI: 10.1371/journal.pone.0124446]
 - 85 **Wang DD**, Bakhotmah BA, Hu FB, Alzahrani HA. Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: a cross-sectional study. *PLoS One* 2014; **9**: e106935 [PMID: 25184511 DOI: 10.1371/journal.pone.0106935]
 - 86 **Al-Adsani AM**. Risk factors for diabetic retinopathy in Kuwaiti type 2 diabetic patients. *Saudi Med J* 2007; **28**: 579-583 [PMID: 17457481]
 - 87 **Al-Maskari F**, El-Sadig M. Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey. *BMC Ophthalmol* 2007; **7**: 11 [PMID: 17572909 DOI: 10.1186/1471-2415-7-11]
 - 88 **Al-Salman RA**, Al-Basri HA, Al-Sayyad AS, Hearnshaw HM. Prevalence and risk factors of albuminuria in Type 2 diabetes in Bahrain. *J Endocrinol Invest* 2009; **32**: 746-751 [PMID: 20009501 DOI: 10.1007/BF03346530]
 - 89 **Al-Mahroos F**, Al-Roomi K. Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study. *Ann Saudi Med* 2007; **27**: 25-31 [PMID: 17277500 DOI: 10.4103/0256-4947.51536]
 - 90 **Bener A**, Al-Laftah F, Al-Hamaq AO, Daghash M, Abdullatef WK. A study of diabetes complications in an endogamous population: an emerging public health burden. *Diabetes Metab Syndr* 2014; **8**: 108-114 [PMID: 24907176 DOI: 10.1016/j.dsx.2014.04.005]
 - 91 **Elshafei M**, Gamra H, Khandekar R, Al Hashimi M, Pai A, Ahmed MF. Prevalence and determinants of diabetic retinopathy among persons ≥ 40 years of age with diabetes in Qatar: a community-based survey. *Eur J Ophthalmol* 2011; **21**: 39-47 [PMID: 20602322 DOI: 10.5301/EJO.2010.2699]
 - 92 **Khandekar R**, Al Lawatii J, Mohammed AJ, Al Raisi A. Diabetic retinopathy in Oman: a hospital based study. *Br J Ophthalmol* 2003; **87**: 1061-1064 [PMID: 12928265]
 - 93 **Khandekar RB**, Tirumurthy S, Al-Harby S, Moorthy NS, Amir I. Diabetic retinopathy and ocular co-morbidities among persons with diabetes at Sumail Hospital of Oman. *Diabetes Technol Ther* 2009; **11**: 675-679 [PMID: 19821761 DOI: 10.1089/dia.2009.0032]
 - 94 **Al-Lawati JA**, N Barakat M, Al-Zakwani I, Elsayed MK, Al-Maskari M, M Al-Lawati N, Mohammed AJ. Control of risk factors for cardiovascular disease among adults with previously diagnosed type 2 diabetes mellitus: a descriptive study from a middle eastern arab population. *Open Cardiovasc Med J* 2012; **6**: 133-140 [PMID: 23166566 DOI: 10.2174/1874192401206010133]
 - 95 **Alrawahi AH**, Rizvi SG, Al-Riyami D, Al-Anqoodi Z. Prevalence and risk factors of diabetic nephropathy in omani type 2 diabetics in Al-dakhiliyah region. *Oman Med J* 2012; **27**: 212-216 [PMID: 22811770 DOI: 10.5001/omj.2012.48]
 - 96 **Al-Akily SA**, Bamashmus MA, Gunaid AA. Causes of visual impairment and blindness among Yemenis with diabetes: a hospital-based study. *East Mediterr Health J* 2011; **17**: 831-837 [PMID: 22276490]
 - 97 **Bamashmus MA**, Gunaid AA, Khandekar RB. Diabetic retinopathy, visual impairment and ocular status among patients with diabetes mellitus in Yemen: a hospital-based study. *Indian J Ophthalmol* 2009; **57**: 293-298 [PMID: 19574698 DOI: 10.4103/0301-4738.53055]
 - 98 **Gunaid AA**, El Khally FM, Hassan NA, Mukhtar el D. Demographic and clinical features of diabetes mellitus in 1095 Yemeni patients. *Ann Saudi Med* 1997; **17**: 402-409 [PMID: 17353590]
 - 99 **Al-Khawlani A**, Atef ZA, Al-Ansi A. Macrovascular complications and their associated risk factors in type 2 diabetic patients in Sana' a city, Yemen. *East Mediterr Health J* 2010; **16**: 851-858 [PMID: 21469567]
 - 100 **Rabiu MM**, Al Bdour MD, Abu Ameerh MA, Jadoon MZ. Prevalence of blindness and diabetic retinopathy in northern Jordan. *Eur J Ophthalmol* 2015; **25**: 320-327 [PMID: 25684158 DOI: 10.5301/ejo.5000557]
 - 101 **Al-Bdour MD**, Al-Till MI, Abu Samra KM. Risk Factors for Diabetic Retinopathy among Jordanian Diabetics. *Middle East Afr J Ophthalmol* 2008; **15**: 77-80 [PMID: 21346842 DOI: 10.4103/0974-9233.51997]
 - 102 **Al-Till MI**, Al-Bdour MD, Ajlouni KM. Prevalence of blindness and visual impairment among Jordanian diabetics. *Eur J Ophthalmol* 2005; **15**: 62-68 [PMID: 15751241]
 - 103 **Jbour AS**, Jarrah NS, Radaideh AM, Shegem NS, Bader IM, Batieha AM, Ajlouni KM. Prevalence and predictors of diabetic foot syndrome in type 2 diabetes mellitus in Jordan. *Saudi Med J* 2003; **24**: 761-764 [PMID: 12883610]
 - 104 **Mackey TA**, Khater N, Al-Zamil MA, El Fishawy H, Soliman MM. Epidemiology of diabetic retinopathy in Egypt: a hospital-based study. *Ophthalmic Res* 2011; **45**: 73-78 [PMID: 20714195 DOI: 10.1159/000314876]
 - 105 **Assaad-Khalil SH**, Zaki A, Abdel Rehman A, Megallaa MH, Gaber N, Gamal H, Rohoma KH. Prevalence of diabetic foot disorders and related risk factors among Egyptian subjects with diabetes. *Prim Care Diabetes* 2015; **9**: 297-303 [PMID: 25543864 DOI: 10.1016/j.pcd.2014.10.010]
 - 106 **Kahloun R**, Jelliti B, Zaouali S, Attia S, Ben Yahia S, Resnikoff S, Khairallah M. Prevalence and causes of visual impairment in diabetic patients in Tunisia, North Africa. *Eye (Lond)* 2014; **28**: 986-991 [PMID: 24924439 DOI: 10.1038/eye.2014.131]
 - 107 **Elhwuegi AS**, Darez AA, Langa AM, Bashaga NA. Cross-sectional pilot study about the health status of diabetic patients in city of Misurata, Libya. *Afr Health Sci* 2012; **12**: 81-86 [PMID: 23066426]

P- Reviewer: Gómez-Sáez JM, Papazoglou D, Tziomalos K

S- Editor: Ji FF **L- Editor:** A **E- Editor:** Liu SQ



Comment on: Statin use and risk of diabetes mellitus

Mehmet Ali Eren, Tevfik Sabuncu, Hüseyin Karaaslan

Mehmet Ali Eren, Tevfik Sabuncu, Hüseyin Karaaslan, Department of Endocrinology, Harran University, School of Medicine, 63100 Sanliurfa, Turkey

Author contributions: Eren MA and Karaaslan H wrote this letter; Sabuncu T edited and revised this letter.

Conflict-of-interest statement: None.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Correspondence to: Mehmet Ali Eren, MD, Department of Endocrinology, Harran University, School of Medicine, Valikonagi Street, Yenisehir Campus, 63100 Sanliurfa, Turkey. drmalieren@hotmail.com
 Telephone: +90-414-3128456

Received: December 11, 2015
 Peer-review started: December 14, 2015
 First decision: January 4, 2016
 Revised: January 22, 2016
 Accepted: February 16, 2016
 Article in press: February 17, 2016
 Published online: April 25, 2016

Abstract

In manuscript named "Statin use and risk of diabetes mellitus" by Chogtu *et al*, authors defined that pravastatin 40 mg/dL reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study. In fact, pravastatin 40 mg/dL reduced coronary heart disease risk approximately 30% in mentioned study.

Key words: Pravastatin; Statins; Diabetes mellitus;

Coronary heart disease; Myocardial Infarction

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We want to eliminate an important error that lead to confusion about the risk of diabetes due to statins in the well-written manuscript by Chogtu *et al*.

Eren MA, Sabuncu T, Karaaslan H. Comment on: Statin use and risk of diabetes mellitus. *World J Diabetes* 2016; 7(8): 175-176 Available from: URL: <http://www.wjgnet.com/1948-9358/full/v7/i8/175.htm> DOI: <http://dx.doi.org/10.4239/wjd.v7.i8.175>

TO THE EDITOR

We read with great interest the recent review by Chogtu *et al*^[1] dealing with the risk of diabetes mellitus development induced by the use of statins. The authors clearly explained the benefit of statin on cardiovascular prevention as well as the possible mechanism of impaired glucose metabolism related with statin. In our opinion, there was a critical confusing error in "statins in diabetes" section.

In the last sentence of mentioned section, authors defined that pravastatin 40 mg/dL reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study with reference to the Kotseva *et al*^[2]. However, pravastatin 40 mg/dL reduced nonfatal myocardial infarctions risk by 31%, death from coronary heart disease by 28%, death from all cardiovascular causes by 32% but there was no information about diabetes risk in the original study of West of Scotland Coronary Prevention Study Group^[3].

We hope that the correction of above-mentioned item would eliminate the confusion and provide better understanding of the well-written manuscript by Chogtu *et al*^[1].

REFERENCES

- 1 **Chogtu B**, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. *World J Diabetes* 2015; **6**: 352-357 [PMID: 25789118 DOI: 10.4239/wjd.v6.i2.352]
- 2 **Kotseva K**, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. *Lancet* 2009; **373**: 929-940 [PMID: 19286092 DOI: 10.1016/S0140-6736(09)60330-5]
- 3 **Shepherd J**, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995; **333**: 1301-1307 [PMID: 7566020 DOI: 10.1056/NEJM199511163332001]

P- Reviewer: Laguna JC, Markopoulos AK, Nagaya M

S- Editor: Ji FF **L- Editor:** A **E- Editor:** Liu SQ





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

